Joshua Farhadian, FAAD, MD
Research & Publications
Biography
Research Summary
I've had an interest in cancer research since childhood, after a close family member was diagnosed with leukemia. Since my undergraduate years, I've been involved in both laboratory and clinical research. My work has focused primarily on signaling pathways in melanoma and trying to identify novel targets that can be translated into pharmacological treatments.
Extensive Research Description
My interest in cancer research stems from my childhood, when a close family was diagnosed with leukemia.
While an undergraduate at the University of Pennsylvania, I had my first cancer research experience working in a lab at the Feinstein Institute for Medical Research. My research there focused on the mechanism by which a protein named MRK is activated and mediates cell cycle arrest in response to ionizing radiation. Subsequently, while a medical student in the honors program at New York University School of Medicine, I continued performing cancer research in the Philips Lab, where I investigated the regulation of a molecule named isoprenylcysteine carboxymethyl transferase (ICMT), which is a protein that plays a role in approximately 25% of all cancers, including skin cancers.
As a medical student at NYU, I completed a year-long research fellowship with the Interdisciplinary Melanoma Cooperative Group (IMCG) at NYU. Supported by grants from the American Medical Association and the American Skin Association, I, along with my colleagues, uncovered nodular melanoma-specific molecular alterations that are pharmacologically targetable in vitro. Additionally, through our work on melanoma brain metastases and microRNA expression in BRAF mutant primary tumors, we identified previously unknown characteristics of melanoma that may one-day influence its management and treatment.
Since medical school, I have been involved a variety of skin cancer related clinical studies. Most recently, my colleagues and I have researched histologic phenotypes that impart aggressive behavior in squamous cell carcinoma. By identifying high risk features, we hope to help stratify patient
Coauthors
Selected Publications
- Pulsed Dye Laser at Subpurpuric Settings for the Treatment of Pulsed Dye Laser–Induced Ecchymoses in Patients With Port-Wine StainsBrauer JA, Farhadian JA, Bernstein LJ, Bae YS, Geronemus RG. Pulsed Dye Laser at Subpurpuric Settings for the Treatment of Pulsed Dye Laser–Induced Ecchymoses in Patients With Port-Wine Stains. Dermatologic Surgery 2018, 44: 220-226. PMID: 28858925, DOI: 10.1097/dss.0000000000001255.
- Trimethoprim-Sulfamethoxazole-Induced Subcutaneous Sweet's Syndrome Masquerading as Septic ShockHase J, Ma H, Wu B, Adelman M, Farhadian J, Femia A, Meehan S, Schwartz D. Trimethoprim-Sulfamethoxazole-Induced Subcutaneous Sweet's Syndrome Masquerading as Septic Shock. CHEST Journal 2016, 150: 376a. DOI: 10.1016/j.chest.2016.08.389.
- Skin-limited relapse of systemic anaplastic large-cell lymphoma.Farhadian JA, Terushkin V, Meehan SA, Kornreich C. Skin-limited relapse of systemic anaplastic large-cell lymphoma. Dermatology Online Journal 2016, 22 PMID: 28329531, DOI: 10.5070/d32212033374.
- Primary cutaneous marginal-zone lymphoma.Farhadian J, Terushkin V, Meehan SA, Latkowski JA. Primary cutaneous marginal-zone lymphoma. Dermatology Online Journal 2016, 22 PMID: 28329553, DOI: 10.5070/d32212033397.
- Male Aesthetics: A Review of Facial Anatomy and Pertinent Clinical Implications.Farhadian JA, Bloom BS, Brauer JA. Male Aesthetics: A Review of Facial Anatomy and Pertinent Clinical Implications. Journal Of Drugs In Dermatology 2015, 14: 1029-34. PMID: 26355624.
- Abstract A14: Hyperactivation of RSK1 is a hallmark of metastatic nodular melanomaSalhi A, Farhadian J, Giles K, Miera E, Silva I, Bourque C, Yeh K, Chhangawala S, Wang J, Ye F, Zhang D, Hernando-Monge E, Houvras Y, Osman I. Abstract A14: Hyperactivation of RSK1 is a hallmark of metastatic nodular melanoma. 2015, a14-a14. DOI: 10.1158/1538-7445.mel2014-a14.
- RSK1 activation promotes invasion in nodular melanomaSalhi A, Farhadian J, Giles K, de Miera E, Silva I, Bourque C, Yeh K, Chhangawala S, Wang J, Ye F, Zhang D, Hernando E, Houvras Y, Osman I. RSK1 activation promotes invasion in nodular melanoma. Journal Of Translational Medicine 2015, 13: o2. PMCID: PMC4315266, DOI: 10.1186/1479-5876-13-s1-o2.
- RSK1 Activation Promotes Invasion in Nodular MelanomaSalhi A, Farhadian JA, Giles KM, de Miera E, Silva IP, Bourque C, Yeh K, Chhangawala S, Wang J, Ye F, Zhang DY, Hernando-Monge E, Houvras Y, Osman I. RSK1 Activation Promotes Invasion in Nodular Melanoma. American Journal Of Pathology 2015, 185: 704-716. PMID: 25579842, PMCID: PMC4348467, DOI: 10.1016/j.ajpath.2014.11.021.
- Angiolymphoid hyperplasia with eosinophilia.Farhadian JA, Shvartsbeyn M, Meehan SA, Urbanek RW. Angiolymphoid hyperplasia with eosinophilia. Dermatology Online Journal 2015, 21 PMID: 26990330, DOI: 10.5070/d32112029531.
- IgA vasculitis (Henoch-Schönlein purpura).Farhadian JA, Castilla C, Shvartsbeyn M, Meehan SA, Neimann A, Pomeranz MK. IgA vasculitis (Henoch-Schönlein purpura). Dermatology Online Journal 2015, 21 PMID: 26990342, DOI: 10.5070/d32112029544.
- Crystal deodorant‐induced axillary granulomatous dermatitisLeventhal JS, Farhadian JA, Miller KE, Tlougan BE, Patel RR, Sanchez MR. Crystal deodorant‐induced axillary granulomatous dermatitis. International Journal Of Dermatology 2013, 53: e59-e60. PMID: 23621443, DOI: 10.1111/j.1365-4632.2012.05686.x.
- Skin Conditions of Baseball, Cricket, and Softball PlayersFarhadian JA, Tlougan BE, Adams BB, Leventhal JS, Sanchez MR. Skin Conditions of Baseball, Cricket, and Softball Players. Sports Medicine 2013, 43: 575-589. PMID: 23456491, DOI: 10.1007/s40279-013-0022-4.
- Elucidating distinct tumorigenic pathways in nodular versus superficial spreading melanoma.Farhadian J, O'Reilly K, Vega-Saenz de Miera E, Ye F, Zavadil J, Taunton J, Zhang D, Osman I. Elucidating distinct tumorigenic pathways in nodular versus superficial spreading melanoma. Journal Of Clinical Oncology 2012, 30: 8544-8544. DOI: 10.1200/jco.2012.30.15_suppl.8544.
- MicroRNA alterations associated with BRAF status in melanoma.Ma M, Farhadian J, Friedman E, Vega-Saenz de Miera E, Hanniford D, Segura M, Berman R, Shapiro R, Pavlick A, Zavadil J, Hernando E, Osman I. MicroRNA alterations associated with BRAF status in melanoma. Journal Of Clinical Oncology 2012, 30: 8565-8565. DOI: 10.1200/jco.2012.30.15_suppl.8565.